What the trials found
The approval was based on the TEMPO clinical trial program. Drug Topics reported that TEMPO-1 enrolled 529 adults with early Parkinson's disease, and TEMPO-3 enrolled 507 adults who experienced motor fluctuations while taking levodopa.
In TEMPO-3, according to AbbVie, daily 'on' time without dyskinesia, a type of involuntary movement, increased by 1.7 hours with tavapadon compared with 0.6 hours with placebo. The Michael J. Fox Foundation summarized the add-on results as roughly one more hour of improved symptom control per day and about one hour less 'off' time.
Side effects were common. Medical Daily reported that in TEMPO-1, 64 of 354 patients taking the drug (18.1%) stopped treatment because of adverse events, compared with 7 of 175 on placebo (4.0%). In TEMPO-2, nausea occurred in 30% of patients, headache in 17% and dizziness in 16%, according to Medical Daily. AbbVie lists orthostatic hypotension, hallucinations, dyskinesia and unusual urges among the more serious safety concerns.
Dr. Hubert Fernandez of Cleveland Clinic told Medical Daily that side effects of interest such as sudden sleep attacks and impulse control problems were more common with older D2 agonists: "D1-targeting drugs are not exempt, but the representation of adverse effects of interest was much higher with D2 agonists."